Pramipexole Teva

USDailyMed:Pramipexole AU:B3 N04BC05(WHO) BR:Class C1(Other controlled substances)CA:℞-onlyUS:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) (S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine 104632-26-0Y 119570 953 DB00413Y 106770Y 83619PEU5T D05575Yas salt:D00559Y CHEBI:8356Y ChEMBL301265Y G6L (PDBe,RCSB PDB) DTXSID6023496 Interactive image n1c2c(sc1N)C[C@@H](NCCC)CC2 InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1YKey:FASDKYOPVNHBLU-ZETCQYMHSA-NY Pramipexole, sold under the brandMirapexamong others, is a medication used to treatParkinson's diseaseandrestless legs syndrome.In Parkinson's disease it may be used alone or together withlevodopa.It is takenby mouth.Pramipexole is adopamine agonistof the non-ergolineclass. Pramipexole was approved for medical use in the United States in 1997and was first manufactured byPharmaciaandUpjohn.It is available as ageneric medication.In 2023, it was the 201st most commonly prescribed medication in the United States, with more than 2million prescriptions.